Case report reveals low ADAMTS13 activity in a pregnant woman, suggesting plasma treatment is crucial to prevent complications.
Key Points
Early diagnosis of congenital thrombotic thrombocytopenic purpura is critical to prevent complications for both mother and fetus.
The patient had an ADAMTS13 activity of less than 5%, highlighting severe enzyme deficiency and diagnostic challenges.
Genetic testing identified two pathogenic ADAMTS13 variants, providing essential confirmation for treatment decisions.
Guidelines exist for managing congenital thrombotic thrombocytopenic purpura, but individualized strategies are necessary for pregnancy and postpartum care.
Cite This Study
González‐Resina et al. (2025) studied this question.